Evidence map›Paper›PMID 40563231›Full record

ArticleImmunology2025

Palmitoylethanolamide (PEA) Induces an Increase in Spleen Regulatory T Cells, Reduces CD8

Bárbara Betônico Berg, Zara Desiree Tonidandel Campos, Gioconda Muniz Fiorenza Ruggio, Ana Flávia Santos Linhares, Bárbara Maximino Rezende, Stêfany Bruno de Assis Cau, Thiago Roberto Lima Romero, Mauro Martins Teixeira, Vanessa Pinho, Marina Gomes Miranda Castor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bárbara Betônico BergGraduate Program in Biological Sciences: Physiology and Pharmacology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Zara Desiree Tonidandel CamposGraduate Program in Biological Sciences: Physiology and Pharmacology, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0009-0003-1280-4532
Gioconda Muniz Fiorenza RuggioGraduate Program in Biological Sciences: Physiology and Pharmacology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Ana Flávia Santos LinharesGraduate Program in Biological Sciences: Physiology and Pharmacology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Bárbara Maximino RezendeDepartment of Nursing, School of Nursing, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Stêfany Bruno de Assis CauDepartment of Pharmacology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Thiago Roberto Lima RomeroDepartment of Pharmacology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Mauro Martins TeixeiraDepartment of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Vanessa PinhoDepartment of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Marina Gomes Miranda CastorDepartment of Pharmacology, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0003-4129-8715

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 306923-2021-1Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-01307-14Pró-Reitoria de Pesquisa, Universidade Federal de Minas Gerais 307-05/2016
6 · The paper itself

Abstract

Graft-versus-host disease (GVHD), a secondary complication of bone marrow transplantation, leads to the development of a systemic inflammatory illness in the host, resulting in high mortality and morbidity. Current therapies lack prophylactic effectiveness and often fail to achieve an optimal immunological balance between inflammation and immunosuppression. In this study, we investigated the effects of palmitoylethanolamide (PEA), an endocannabinoid-like lipid mediator with extensively documented anti-inflammatory, analgesic, antimicrobial, immunomodulatory, and neuroprotective effects, on the complex pathology of GVHD. Treatment with PEA reduced clinical disease severity in GVHD mice, leading to an 80% increase in survival rates. Additionally, PEA created an immunoregulatory environment in the spleen by reducing the activation of CD3

Indexed as

CD8-Positive T-LymphocytesEthanolaminesGraft vs Host DiseasePalmitic AcidsPPAR gammaSpleenT-Lymphocytes, RegulatoryTumor Necrosis Factor-alphaAmidesAnimalsBone Marrow TransplantationDisease Models, AnimalEndocannabinoidsMiceMice, Inbred BALB CMice, Inbred C57BLAmidesEndocannabinoidsEthanolaminespalmidrolPalmitic AcidsPPAR gammaTumor Necrosis Factor-alphaendocannabinoidsgraft‐versus‐host diseaseinflammation

Identifiers

PMID40563231
PMCPMC12500389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.